Bloomberg Intelligence cover image

Novo Halves Ozempic Price to $499 a Month For Those Paying Cash

Bloomberg Intelligence

00:00

Intro

This chapter examines Novo's recent decision to lower the price of Ozempic to $499 per month for cash payers, analyzing its impact on patient accessibility. It also discusses wider trends in pharmaceutical pricing and healthcare savings strategies.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app